Apoptosis assessment in acute myeloid leukemia and B-cell chronic lymphocytic leukemia cells after in vitro cytostatics treatment and its relationship to multidrug resistance

Czech version

Authors: K. Jankovičová ¹; J. Krejsek ¹; O. Kopecký ¹; J. Voglová ²; Z. Škrabková ³; J. Novosad ¹
Authors‘ workplace: Ústav klinické imunologie a alergologie Lékařské fakulty UK a FN Hradec Králové, přednosta MUDr. Otakar Kopecký, CSc. ¹; Oddělení klinické hematologie FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc. ²; Ústav lékařské biofyziky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Pravoslav Stránský, CSc. ³
Published in: Vnitř Lék 2005; 51(2): 175-182
Category: Original Contributions

Overview

Apoptosis failure during chemotherapy of leukemia is one of the multidrug resistance mechanisms. The aim of this study was to introduce in vitro model for malignant cell clone sensitivity testing. In vitro cytostatic treatment of acute myeloid leukemia (AML) and B-cell chronic lymphocytic leukemia (B-CLL) cells and its relationship to P-gp, MRP, LRP, Bcl-2, and Bax proteins expression was also investigated. AML cells were treated with doxorubicin and B-CLL cells were treated with chlorambucil. Flow cytometry was used for all experiments evaluation. To detect the amount of apoptotic cells in the sample three methods were used: annexin test, TUNEL (Tdt-mediated dUTP nick end labeling) test, and caspase 8 detection. After in vitro cytostatic treatment statistically significant increase in the number of apoptotic cells in the culture in the case of AML cells but not in the case of B-CLL cells was observed. When analysing multidrug resistance markers some tendencies to correlate with in vitro apoptosis reaction of AML and B-CLL cells were found above all by P-gp and Bcl-2 markers. AML cells displayed negative correlation between P-gp function and number of apoptotic cells detected by TUNEL test. B-CLL cells demonstrated negative correlation between P-gp expression and number of apoptotic cells detected by annexin test and negative correlation between Bcl-2 and caspase 8 expression.

Key words:
acute myeloid leukemia – B-cell chronic lymphocytic leukemia – apoptosis – multidrug resistance – flow cytometry

Sources

1. Arceci RJ. Can multidrug resistance mechanisms be modified? Br J Haematol 2000; 110: 285–291.

2. Aviram A, Rabizadeh E, Zuira Y et al. Expression of bcl-2 and bax in cells isolated from B chronic lymphocytic leukemia patients at different stages of the disease. Eur J Haematol 2000; 64: 80–84.

3. Baisch H, Bollmann H, Bornkessel S. Degradation of apoptotic cells and fragments in HL-60 suspension cultures after induction of apoptosis by camptothecin and ethanol. Cell Prolif 1999; 32: 303–319.

4. Banker DE, Cooper JJ, Fennell DA et al. PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. Leuk Res 2002; 26: 91–106.

5. Banker DE, Groudine M, Willman CL et al. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. Leuk Res 1998; 22: 221–239.

6. Beck WT, Grogan TM. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia 1997; 11: 1107–1109.

7. Brügger D, Herbart H, Gekeler V et al. Functional analysis of P–glycoprotein and multidrug resistance associated protein related multidrug resistance in AML–blasts. Leuk Res 1999; 123: 467–475.

8. Dive C. Avoidance of apoptosis as a mechanism of drug resistance. J Int Med 1997; 242(Suppl 740): 139–145.

9. Efferth T, Fabry U, Osieka R. Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 1997; 11: 1180–1186.

10. Elkon KB. Caspases: Multifunctional proteases. J Exp Med 1999; 190: 1725–1727.

11. Fennell DA, Cotter FE. Controlling the mitochondrial gatekeeper for effective chemotherapy. Br J Haematol 2000; 111: 52–60.

12. Filipits M, Stranzl T, Pohl G et al. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia 2000; 14: 68–76.

13. Gamberale R, Geffner JR, Trevani A et al. Immune complexes inhibit apoptosis of chronic lymphocytic leukaemia B cells. Br J Haematol 1999; 107: 870–876.

14. Gorman AM, Samali A, McGowan AJ et al. Use of flow cytometry techniques in studying mechanisms of apoptosis in leukemic cells. Cytometry 1997; 29: 97–105.

15. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Canc 1996; 32A: 921–926.

16. Higashi Y, Turzanski J, Pallis M et al. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in Pglycoprotein-positive and P-glycoprotein–negative acute myeloblastic leukaemia. Br J Haematol 2000; 111: 565–569.

17. Inohara N, Ding L, Chen S et al. HARAKIRI, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival – promoting proteins Bcl-2 and Bcl-XL. EMBO J 1997; 16: 1686–1694

18. Jankovičová K, Krejsek J, Kopecký O. Mnohočetná rezistence leukemických buněk k cytostatikům – funkční testy akumulace fluorescenčních barviv hodnocené průtokovou cytometrií. Vnitř Lék 2001; 47: 25–29.

19. Jia L, Liu KZ, Newland AC et al. Pgppositive leukaemic cells have increased mtDNA but no icreased rate of proliferation. Br J Haematol 1999; 107: 861–869.

20. Klein A, Miera O, Bauer O et al. Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia 2000; 14: 40–46.

21. Krishan A, Morgan FC, Andritsch I. Drug retention, efflux and resistance in tumor cells. Cytometry 1997; 29: 279–285.

22. Lundin J, Kimby E, Bergmann L et al. Interleukin 4 therapy for patients with chronic lymphocytic leukemia: a phase I/II study. Br J Haematol 2001; 112: 155–160.

23. Marie JP, Huet S, Faussat AM et al. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 1997; 11: 1086–1094.

24. Okochi E, Iwahashi T, Tsuruo T. Monoclonal antibodies specific for P-glycoprotein. Leukemia 1997; 11: 1119–1123.

25. Pallis M, Russell NH. Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation. Br J Haematol 1998; 100: 194–197.

26. Pallis M, Turzanski J, Harrison G et al. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. Br J Haematol 1999; 104: 307–312.

27. Pepper C, Thomas A, Hoy T et al. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br J Haematol 1999; 104: 581–588.

28. Pepper C, Thomas A, Hoy T et al. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 107: 611–615.

29. Ramachandran C, Melnick SJ. Multidrug resistance in human tumors – molecular diagnosis and clinical significance. Mol Diagnosis 1999; 4: 81–94.

30. Reed JC. Bcl-2 family protein and mechanisms of chemoresistance in lymphomas and leukemias. Adv Leuk Lymph 1995; 5: 3–11.

31. Reed JC. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematological malignancies. Sem Hematol 1997; 34: 9–19.

32. Robert J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eu J Clin Invest 1999; 29: 536–545.

33. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 2000; 14: 467–473.

34. Ruefli AA, Bernhard D, Tainton KM et al. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoproteinexpressing cells. Int J Cancer 2002; 99: 292–298.

35. Ruth AC, Roninson IB. Effects of the multidrug transporter P-glycoprotein on cellular responses to ioniziing radiation. Cancer Res 2000; 60: 2576–2578.

36. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest 1999; 104: 1655–1661.

37. van den Heuvel-Eibrink MM, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Therapeutics

2000; 38: 94–110.

38. Vermes I, Haanen C, Richel DJ et al. Apoptosis and secondary necrosis of lymphocytes in culture. Acta Haematol 1997; 98: 8–13.

39. Wickremasinghe RG, Hoffbrand AV. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood 1999; 93: 3587–3600.

40. Wuchter C, Karawajew L, Ruppert V et al. Clinical significance of CD95,Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 1999; 13: 1943–1953.

41. Xerri L, Devilard E, Bouabdallah R et al. FADD expression and caspase activation in B-cell lymphomas resistant to Fas-mediated apoptosis. Br J Haematol 1999; 106: 652–661.